Gerresheimer AG stock (DE000A0LD6E6): Valuation focus after Q1 2026 earnings update

Gerresheimer AG shares in Germany trade close to recent levels after the company reported higher Q1 2026 revenue and adjusted EBITDA and confirmed its full-year 2026 outlook, keeping valuation metrics in focus for investors.

Gerresheimer AG shares continue to trade in a relatively narrow range on the Xetra segment of Deutsche Börse in Germany after the company released its Q1 2026 results and reiterated its full-year 2026 guidance, leaving investors focused on updated valuation metrics and earnings visibility for the rest of the year, according to Xetra data and the latest company disclosures as of 05/06/2026.

In its Q1 2026 earnings statement dated 04/10/2026, Gerresheimer reported that group revenue increased to EUR 538 million for the quarter ended 02/29/2026, compared with EUR 502 million in Q1 2025, while adjusted EBITDA rose to EUR 106 million from EUR 97 million, according to the company’s investor relations communication on 04/10/2026.

The company also confirmed in the same 04/10/2026 release that its full-year 2026 outlook remains unchanged, targeting organic revenue growth in the mid-single-digit percentage range and an adjusted EBITDA margin in the high teens for the financial year ending 11/30/2026, based on its published guidance framework as of that date.

On the home market in Germany, Gerresheimer’s stock is listed on Xetra under the ticker GXI and forms part of the MDAX index, giving it visibility among mid-cap industrial and healthcare suppliers to the global pharmaceuticals and life sciences sectors, according to Deutsche Börse information as of 05/06/2026.

As of 05/06/2026, the stock traded at EUR 27.91 on Xetra in Frankfurt, valuing the company at approximately EUR 965.7 million in market capitalization and implying a price-to-earnings ratio of 8.79 based on a 2024 net income figure of EUR 109.7 million and 34.5 million shares outstanding, according to BörsenNEWS.de data published on 05/06/2026.

In addition to its home Xetra listing, Gerresheimer shares are also traded on German retail platforms such as Tradegate, where the stock has recently changed hands at prices close to the Xetra quote, offering German private investors alternative access to liquidity in the name alongside the primary exchange, according to Tradegate quote information as of 05/06/2026.

As of: 05/06/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Gerresheimer
• Sector/industry: Medical packaging and drug delivery solutions
• Headquarters/country: Düsseldorf, Germany
• Core markets: Europe, North America, Asia-Pacific
• Key revenue drivers: Primary packaging for pharmaceuticals, complex drug delivery systems, specialty glass and plastic containers for healthcare and cosmetics
• Home exchange/listing venue: Xetra (GXI)
• Trading currency: EUR

Gerresheimer AG: core business model

Gerresheimer primarily develops and manufactures specialized glass and plastic containers as well as drug delivery devices for pharmaceutical and biotech customers, with its revenue shaped by long-term supply contracts, regulatory-driven demand for injectable and oral drug packaging, and the expansion of complex delivery systems such as prefillable syringes and autoinjectors.

Valuation metrics and multiples for Gerresheimer AG

Following the publication of its Q1 2026 figures on 04/10/2026, investors have further data points to assess Gerresheimer’s valuation, particularly the relationship between its earnings power and current share price levels expressed through multiples such as the price-to-earnings ratio and enterprise value to EBITDA.

According to BörsenNEWS.de as of 05/06/2026, the company’s calculated price-to-earnings ratio of 8.79 is based on a 2024 net profit of EUR 109.7 million divided by approximately 34.5 million shares outstanding and multiplied by a Xetra share price of EUR 27.91, while the website also cites an earnings per share figure of EUR 2.665 and a dividend per share of EUR 0.04 for 2024, which together offer a starting point for comparing Gerresheimer’s valuation and income profile to other listed packaging and healthcare suppliers.

From a cash flow and profitability perspective, the Q1 2026 adjusted EBITDA of EUR 106 million reported by Gerresheimer on 04/10/2026, when set against its market capitalization of around EUR 965.7 million as per BörsenNEWS.de on 05/06/2026, suggests an annualized implied EV/EBITDA multiple that investors can benchmark to sector peers, although a full enterprise value calculation would also incorporate the company’s net debt as disclosed in its financial statements.

Conclusion

Gerresheimer AG’s Q1 2026 revenue of EUR 538 million and adjusted EBITDA of EUR 106 million, as reported on 04/10/2026, provide investors with fresh input on the company’s operating momentum and the resilience of demand for its pharmaceutical packaging and drug delivery solutions.

At the same time, the current Xetra share price of EUR 27.91 and the implied 2024 price-to-earnings ratio of 8.79, based on net income of EUR 109.7 million and 34.5 million shares outstanding as referenced by BörsenNEWS.de on 05/06/2026, frame the valuation discussion that will likely guide investor expectations ahead of the next quarterly update.

How the balance between growth, profitability, and capital returns such as the EUR 0.04 per share dividend cited for 2024 develops over the course of 2026 will be central to the market’s assessment of Gerresheimer’s long-term positioning within the global healthcare packaging and drug delivery ecosystem.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.